Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Acute Decompensated Heart Failure (Pilot Study)
2017-001679-22Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing Empagliflozin 10 mg/day with Placebo (2 arms). Primary endpoints: Dyspnea relief by VAS from baseline to day 4 (or discharge), Diuretic response during index hospitalization and 2 more. Started Sep 2017; status: active.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2017-001679-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001679-22.